Eli Lilly and Company (LLY) Financials
Eli Lilly and Company (LLY) Historical Financial Statements and Key Metrics for 1994 - 2023
Full Eli Lilly and Company financials for 1994 - 2023 are available in the
US Historical Financials dataset
All financial data is sourced direct from SEC 10-Q and 10-K filings, restatements are included.
Eli Lilly and Company Income Statements
(in $ 000,000's)
| Quarter End | Revenue | Gross Profit | Operating Income | Net Income | EBITDA | EPS |
| 2023-Jun-30 | 8,312 | 6,505 (78.3 %) | 2,126 (25.6 %) | 1,763 (21.2 %) | 2,320 | 1.95 |
| 2023-Mar-31 | 6,960 | 5,333 (76.6 %) | 1,494 (21.5 %) | 1,345 (19.3 %) | 1,704 | 1.49 |
| 2022-Dec-31 | 7,302 | 5,754 (78.8 %) | 1,836 (25.1 %) | 1,938 (26.5 %) | 2,555 | 2.04 |
| 2022-Sep-30 | 0 | 0 (0.0 %) | 0 (0.0 %) | 0 (0.0 %) | 0 | 0.00 |
| 2022-Jun-30 | 6,488 | 5,058 (78.0 %) | 1,650 (25.4 %) | 952 (14.7 %) | 1,521 | 1.05 |
| 2022-Mar-31 | 7,810 | 5,738 (73.5 %) | 2,404 (30.8 %) | 1,903 (24.4 %) | 1,976 | 2.00 |
| 2021-Dec-31 | 8,000 | 5,950 (74.4 %) | 1,917 (24.0 %) | 1,726 (21.6 %) | 2,367 | 1.81 |
Full historical income statements for 1994 - 2023 is included in the
US Historical Financials dataset.
Eli Lilly and Company Balance Sheets
(in $ 000,000's)
| Quarter End | Total Assets | Total Liabilities | Total Debt | Total Equity | Cash & Equivalents |
| 2023-Jun-30 | 54,814 | 43,665 | 18,820 | 11,064 | 2,829 |
| 2023-Mar-31 | 53,163 | 41,868 | 18,884 | 11,190 | 3,669 |
| 2022-Dec-31 | 49,490 | 38,714 | 16,239 | 10,650 | 2,212 |
| 2022-Sep-30 | 47,462 | 37,296 | 15,888 | 10,070 | 2,742 |
| 2022-Jun-30 | 47,064 | 38,404 | 16,814 | 8,545 | 2,737 |
| 2022-Mar-31 | 46,919 | 37,588 | 16,509 | 9,331 | 2,568 |
| 2021-Dec-31 | 48,806 | 39,651 | 16,885 | 8,979 | 3,909 |
Full historical balance sheet data for 1994 - 2023 is included in the
US Historical Financials dataset.
Eli Lilly and Company Cash Flow Statements
(in $ 000,000's)
| Quarter End | Operating Cash Flow | Investing | Financing | Free Cash Flow |
| 2023-Jun-30 | 632 | -459 | -1,033 | -204 |
| 2023-Mar-31 | 1,731 | -689 | 412 | 827 |
| 2022-Dec-31 | 1,580 | -860 | -1,141 | 1,024 |
| 2022-Sep-30 | 2,185 | -923 | -1,263 | 1,565 |
| 2022-Jun-30 | 821 | -464 | -124 | 370 |
| 2022-Mar-31 | 2,499 | -1,014 | -2,878 | 2,134 |
| 2021-Dec-31 | 2,156 | -379 | -1,526 | 1,762 |
Full historical cash flow data for 1994 - 2023 is included in the
US Historical Financials dataset.
Eli Lilly and Company Key Valuation and Operating Metrics
| Quarter End | Market Capitalization ($ 000,000's) |
Enterprise Value ($ 000,000's) |
Price/Earnings ($ 000,000's) |
Price/Sales ($ 000,000's) |
Price/Book ($ 000,000's) |
| 2023-Jun-30 | 421,941 | 438,067 | 50.76 | 59.83 | 38.14 |
| 2023-Mar-31 | 310,205 | 325,543 | 44.57 | 57.66 | 27.72 |
| 2022-Dec-31 | 347,615 | 361,786 | 47.61 | 44.85 | 32.64 |
| 2022-Sep-30 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2022-Jun-30 | 291,904 | 306,095 | 44.99 | 76.62 | 34.16 |
| 2022-Mar-31 | 273,098 | 287,147 | 34.97 | 35.88 | 29.27 |
| 2021-Dec-31 | 263,418 | 276,484 | 32.93 | 38.15 | 29.34 |
Full historical valuation and operating metrics for 1994 - 2023 are included in the
US Historical Financials dataset.